Innate Pharma (Euronext Paris:IPH; NASDAQ:IPHA) and the Institute for Follicular Lymphoma (IFLI) have announced a collaboration agreement to clinically evaluate the potential of Innate’s IPH6501 in follicular lymphoma (FL). Under the terms of the agreement, Innate will receive $3 million upfront and up to $4.9 based on the completion of specified milestones.
Innate’s ongoing Phase 1/2, open-label, multicenter trial—designed to investigate the safety, tolerability, and preliminary antineoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20-expressing Non-Hodgkin Lymphoma—will now also include patients with relapsed/refractory (R/R) FL.
“At Innate Pharma, we are deeply committed to advancing innovative research and development to improve outcomes for patients with non-Hodgkin lymphoma and this agreement with the IFLI will contribute to our mission to bring forward therapeutic options that address critical needs and enhance the quality of life for those affected by this challenging disease,” said Dr. Sonia Quaratino, CMO of Innate.
Dr. Michael Azoulay, CMO of IFLI commented: “IFLI believes IPH6501 holds great promise for improving patient outcomes in non-Hodgkin lymphomas including FL. We are delighted to support Innate and the investigation of IPH6501 in FL patients and, upon milestone achievement, to continue to support future clinical development of IPH6501 in FL. This collaboration provides a model for how IFLI’s philanthropic investments can catalyze FL development.”
